

ASX Announcement

5 April 2024

Resignation of Non-Executive Director – Leo Lee

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises that Non-Executive Director, Mr Leo Lee has resigned from the Company's Board, effective immediately.

Leo joined the Board of Regeneus as Non-Executive Director on 11 December 2017. He brought a wealth of pharmaceutical business experience gained from his senior leadership roles in Allergan and Merck Serono.

On 23 January 2019, Leo was appointed as the CEO of Regeneus to lead the Company to secure its first major clinical licence of Progenza in Japan, and to seek partnerships with potential licensees in key markets. Leo resigned from his role as CEO of the Company on 2 November 2020 to pursue a new role in major Japanese pharmaceutical company Novartis. He remained on the Board of Regeneus as a Non-Executive Director, enabling the Company to benefit from his strategic leadership.

The Board of Regeneus would like to thank Leo for his contribution to Regeneus, assisting the Company in its endeavours to commercialise its lead stem cell technology platform Progenza.

-ENDS-

About Regeneus Ltd (to be renamed Cambium Bio Limited)

Regeneus Ltd (to be renamed Cambium Bio Limited) (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through

clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio or www.regeneus.com.au.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd